No Data
No Data
Express News | Ocugen Inc - on Dec 31, 2024 Receives Nasdaq Notice for Bid Price Deficiency
Ocugen Inc. Stock Falls Tuesday, Underperforms Market
Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy
Express News | Ocugen Inc - Dsmb Approves Continuation of Ocu410 Armada Phase 1/2 Study
Express News | Ocugen Inc: Ocu410 Has a Very Favorable Safety and Tolerability Profile
Express News | Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of Ocu410 Armada Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration